GlassScriptPhysician profile
Andrew Jonathan Sperling
NPI 1932347929
$11,560.71
in general payments reported to CMS, 2019-2025
43 companies · $2,398 in 2025
The $2,398 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,454 · 2020: $1,035 · 2021: $1,250 · 2022: $727 · 2023: $1,620 · 2024: $2,076 · 2025: $2,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,080 · Education: $14.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,080.46 |
| Education | $14.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,784.00 | 2019-2025 | Farxiga, Airsupra, Bevespi Aerosphere |
| Pfizer INC. | $1,718.66 | 2019-2025 | |
| Abbvie INC. | $1,389.39 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $771.37 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $614.04 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $612.93 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $565.64 | 2019-2025 | Repatha, Otezla, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $558.95 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $558.42 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $515.09 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $276.29 | 2019-2023 | Belsomra |
| Otsuka America Pharmaceutical, INC. | $220.90 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.93 | 2019-2025 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $169.69 | 2019-2020 | |
| Exact Sciences Corporation | $143.59 | 2023-2025 | Cologuard Collection Kit |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Sperling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.